PE20141297A1 - Formulaciones peptidicas robustas de liberacion controlada - Google Patents
Formulaciones peptidicas robustas de liberacion controladaInfo
- Publication number
- PE20141297A1 PE20141297A1 PE2014000875A PE2014000875A PE20141297A1 PE 20141297 A1 PE20141297 A1 PE 20141297A1 PE 2014000875 A PE2014000875 A PE 2014000875A PE 2014000875 A PE2014000875 A PE 2014000875A PE 20141297 A1 PE20141297 A1 PE 20141297A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- controlled release
- insaturation
- acil
- chains
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000013270 controlled release Methods 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- VVEJUSYNERNRME-XGFVQVCISA-N (4r,7s,10r,13s,16r,19s,22r,25s,28r,31s)-13,28-bis(4-aminobutyl)-25-(2-amino-2-oxoethyl)-31-[[2-[[(2s)-2-aminopropanoyl]amino]acetyl]amino]-19,22-dibenzyl-10-[(1r)-1-hydroxyethyl]-7-(hydroxymethyl)-16-(1h-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30-nonaoxo- Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N1)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 VVEJUSYNERNRME-XGFVQVCISA-N 0.000 abstract 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 abstract 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
- 101500024338 Homo sapiens Somatostatin-14 Proteins 0.000 abstract 1
- 229940123051 Somatostatin receptor agonist Drugs 0.000 abstract 1
- 102400000820 Somatostatin-14 Human genes 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960001295 tocopherol Drugs 0.000 abstract 1
- 229930003799 tocopherol Natural products 0.000 abstract 1
- 235000010384 tocopherol Nutrition 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
SE REFIERE A UNA PREFORMULACION QUE COMPRENDE UNA MEZCLA CRISTALINA NO LIQUIDA DE BAJA VISCOSIDAD DE: A) 25 A 55% EN PESO DE UN DIACILGLICEROL O UN TOCOFEROL; B) 25 A 55% EN PESO DE FOSFOLIPIDOS QUE TIENEN i) GRUPOS DE CABEZA POLAR QUE COMPRENDEN MAS DEL 50% DE FOSFATIDILETANOLAMINA, Y ii) DOS CADENAS DE ACILO DE 16 A 20 CARBONOS DONDE UNA CADENA DE ACILO TIENE UNA INSATURACION Y NO HAY MAS DE CUATRO INSATURACIONES EN LAS DOS CADENAS; C) 5 A 25% EN PESO DE UN SOLVENTE BIOCOMPATIBLE, ORGANICO, DE BAJA VISCOSIDAD Y QUE CONTIENE OXIGENO TAL COMO ETANOL; Y D) DE 0,1 A 10% EN PESO DE UN AGENTE PEPTIDICO ACTIVO QUE COMPRENDE UN AGONISTA DEL RECEPTOR DE SOMATOSTATINA TAL COMO SST-14, OCTREOTIDA, LANREOTIDA, ENTRE OTROS; EN DONDE LA PREFORMULACION FORMA O TIENE LA CAPACIDAD DE FORMAR UNA ESTRUCTURA DE FASE CRISTALINA LIQUIDA NO LAMINAR AL ENTRAR EN CONTACTO CON UN FLUIDO ACUOSO. DICHA COMPOSICION ES UTIL EN LA LIBERACION CONTROLADA DE PEPTIDOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566851P | 2011-12-05 | 2011-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141297A1 true PE20141297A1 (es) | 2014-10-09 |
Family
ID=47226199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000875A PE20141297A1 (es) | 2011-12-05 | 2012-11-28 | Formulaciones peptidicas robustas de liberacion controlada |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9585959B2 (es) |
| EP (2) | EP2787974B1 (es) |
| JP (2) | JP6081480B2 (es) |
| KR (2) | KR101979051B1 (es) |
| CN (2) | CN104093399B (es) |
| AU (2) | AU2012348641B2 (es) |
| BR (2) | BR112014013693B1 (es) |
| CA (2) | CA2858227C (es) |
| CL (1) | CL2014001472A1 (es) |
| CO (1) | CO7000746A2 (es) |
| DK (2) | DK2787975T3 (es) |
| EA (2) | EA027924B1 (es) |
| ES (2) | ES2645345T3 (es) |
| HR (1) | HRP20170954T1 (es) |
| IL (2) | IL232789B (es) |
| MX (2) | MX350929B (es) |
| PE (1) | PE20141297A1 (es) |
| PL (1) | PL2787975T3 (es) |
| SG (1) | SG11201402673YA (es) |
| SI (1) | SI2787974T1 (es) |
| WO (2) | WO2013083460A1 (es) |
| ZA (1) | ZA201403793B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE401054T1 (de) * | 2004-06-04 | 2008-08-15 | Camurus Ab | Flüssige depotformulierungen |
| GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| TWI624271B (zh) * | 2011-05-25 | 2018-05-21 | 凱慕路斯公司 | 包含低黏度混合物之預調配物及其形成方法，及該低黏度混合物或預調配物之用途 |
| NZ702028A (en) * | 2012-05-25 | 2016-07-29 | Camurus Ab | Somatostatin receptor agonist formulations |
| MX387722B (es) | 2012-07-26 | 2025-03-18 | Camurus Ab | Formulaciones de opioides. |
| EP3326613A1 (en) | 2012-07-26 | 2018-05-30 | Camurus AB | Opioid formulations |
| EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| EP3060230A4 (en) | 2013-10-22 | 2017-06-14 | Prolynx LLC | Conjugates of somatostatin and its analogs |
| WO2016092569A1 (en) * | 2014-12-10 | 2016-06-16 | Council Of Scientific & Industrial Research | A discontinuous reverse micellar composition in cubic fd3m phase for sustained release of therapeutic drugs |
| CA2971642A1 (en) * | 2014-12-23 | 2016-06-30 | Camurus Ab | Controlled-release formulations |
| GB201516554D0 (en) * | 2015-09-18 | 2015-11-04 | Camurus Ab | Controlled-release formulations |
| ITUB20160416A1 (it) * | 2016-01-28 | 2017-07-28 | Italfarmaco Spa | Uso di una formulazione a lento rilascio di octreotide per la prevenzione della formazione di seroma |
| EP3436050A4 (en) * | 2016-03-31 | 2020-01-15 | Sun Pharma Advanced Research Company Limited | LIRAGLUTIDE VISCOELASTIC GEL DESIGNED FOR ADMINISTRATION ONCE A WEEK OR ONCE EVERY TWO WEEKS |
| WO2018060213A1 (en) | 2016-09-27 | 2018-04-05 | Camurus Ab | Formulations containing a somatostatin receptor agonist |
| PL3512495T3 (pl) * | 2016-09-15 | 2023-01-23 | Camurus Ab | Preparaty analogu prostacykliny |
| WO2018217926A1 (en) | 2017-05-24 | 2018-11-29 | Vmr Products Llc | Flavor disk |
| WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| EP4670713A1 (en) | 2018-05-01 | 2025-12-31 | Chibi, Inc. | LIQUID DEPOSIT FOR THE PROLONGED NON-INVASIVE ADMINISTRATION OF AGENTS TO THE IL |
| WO2019213326A1 (en) * | 2018-05-01 | 2019-11-07 | Idrop, Inc. | Eye drop formulation and method for sustained delivery of medicament to the retina |
| CN108498849B (zh) * | 2018-05-08 | 2021-04-30 | 武汉百纳礼康生物制药有限公司 | 一种液晶凝胶肝动脉栓塞剂及其制备方法 |
| CN109091451B (zh) * | 2018-09-10 | 2021-08-13 | 武汉百纳礼康生物制药有限公司 | 亲水性药物的油相液晶凝胶前体制剂及其制备方法 |
| AU2020282018B2 (en) | 2019-05-29 | 2025-12-18 | Camurus Ab | Lipid-controlled release compositions |
| WO2021160887A1 (en) | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
| MX2022016437A (es) * | 2020-06-30 | 2023-01-30 | Chong Kun Dang Pharmaceutical Corp | Composicion inyectable que comprende un analogo de gnrh. |
| WO2022093722A1 (en) * | 2020-10-27 | 2022-05-05 | Pts Consulting, Llc | A liquid injectable composition of donepezil |
| CN113081954A (zh) * | 2021-05-25 | 2021-07-09 | 南昌大学第二附属医院 | 一种凝胶载药贴剂药物输送系统 |
| WO2023008498A1 (ja) * | 2021-07-27 | 2023-02-02 | 株式会社ファルネックス | 非ラメラ液晶形成性組成物及びその用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8206744D0 (sv) | 1982-11-26 | 1982-11-26 | Fluidcarbon International Ab | Preparat for kontrollerad avgivning av substanser |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| WO1995026715A2 (en) * | 1994-03-30 | 1995-10-12 | Dumex-Alpharma A/S | Use of fatty acid esters as bioadhesive substances |
| SE518578C2 (sv) * | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
| ATE272394T1 (de) | 1996-10-31 | 2004-08-15 | Takeda Chemical Industries Ltd | Zubereitung mit verzögerter freisetzung |
| BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| JP3952617B2 (ja) | 1998-12-11 | 2007-08-01 | 株式会社日立製作所 | 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒 |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| CA2542708A1 (en) * | 2003-10-24 | 2005-05-06 | University Of Saskatchewan | Dna delivery with gemini cationic surfactants |
| PL1682091T3 (pl) * | 2003-11-07 | 2017-09-29 | Camurus Ab | Kompozycje lipidów i kationowych peptydów |
| GB0401513D0 (en) | 2004-01-23 | 2004-02-25 | Camurus Ab | Compositions |
| JP4966018B2 (ja) | 2004-01-23 | 2012-07-04 | カムルス エービー | 三元非ラメラ脂質組成物 |
| ATE401054T1 (de) * | 2004-06-04 | 2008-08-15 | Camurus Ab | Flüssige depotformulierungen |
| JP2008502690A (ja) * | 2004-06-15 | 2008-01-31 | アンドリュー シァン チェン， | リン脂質組成物ならびにその調製方法および使用方法 |
| EP1845942B1 (en) | 2005-01-14 | 2014-04-09 | Camurus Ab | Gnrh analogue formulations |
| KR100983746B1 (ko) * | 2005-01-14 | 2010-09-24 | 카무러스 에이비 | 소마토스타틴 유사 제형 |
| CA2595385C (en) | 2005-01-21 | 2011-01-25 | Camurus Ab | Pharmaceutical lipid compositions |
| CA2609810C (en) | 2005-06-06 | 2012-05-22 | Camurus Ab | Glp-1 analogue formulations |
| GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
-
2012
- 2012-11-28 CN CN201280066168.1A patent/CN104093399B/zh active Active
- 2012-11-28 EA EA201491005A patent/EA027924B1/ru not_active IP Right Cessation
- 2012-11-28 EA EA201490921A patent/EA028040B1/ru not_active IP Right Cessation
- 2012-11-28 DK DK12791490.1T patent/DK2787975T3/da active
- 2012-11-28 EP EP12791208.7A patent/EP2787974B1/en active Active
- 2012-11-28 BR BR112014013693-9A patent/BR112014013693B1/pt active IP Right Grant
- 2012-11-28 EP EP12791490.1A patent/EP2787975B1/en active Active
- 2012-11-28 US US14/362,517 patent/US9585959B2/en active Active
- 2012-11-28 JP JP2014545179A patent/JP6081480B2/ja active Active
- 2012-11-28 ES ES12791490.1T patent/ES2645345T3/es active Active
- 2012-11-28 MX MX2014006624A patent/MX350929B/es active IP Right Grant
- 2012-11-28 DK DK12791208.7T patent/DK2787974T3/en active
- 2012-11-28 US US14/362,542 patent/US9555118B2/en active Active
- 2012-11-28 WO PCT/EP2012/073843 patent/WO2013083460A1/en not_active Ceased
- 2012-11-28 SI SI201230991T patent/SI2787974T1/sl unknown
- 2012-11-28 AU AU2012348641A patent/AU2012348641B2/en active Active
- 2012-11-28 PL PL12791490T patent/PL2787975T3/pl unknown
- 2012-11-28 CA CA2858227A patent/CA2858227C/en active Active
- 2012-11-28 ES ES12791208.7T patent/ES2629188T3/es active Active
- 2012-11-28 JP JP2014545177A patent/JP6081479B2/ja active Active
- 2012-11-28 KR KR1020147018186A patent/KR101979051B1/ko active Active
- 2012-11-28 BR BR112014013691A patent/BR112014013691A2/pt not_active Application Discontinuation
- 2012-11-28 WO PCT/EP2012/073841 patent/WO2013083459A1/en not_active Ceased
- 2012-11-28 MX MX2014006625A patent/MX352024B/es active IP Right Grant
- 2012-11-28 SG SG11201402673YA patent/SG11201402673YA/en unknown
- 2012-11-28 PE PE2014000875A patent/PE20141297A1/es not_active Application Discontinuation
- 2012-11-28 CN CN201280066173.2A patent/CN104105479B/zh active Active
- 2012-11-28 KR KR1020147018578A patent/KR20140105527A/ko not_active Ceased
- 2012-11-28 CA CA2857982A patent/CA2857982A1/en not_active Abandoned
- 2012-11-28 HR HRP20170954TT patent/HRP20170954T1/hr unknown
- 2012-11-28 AU AU2012348640A patent/AU2012348640B2/en active Active
-
2014
- 2014-05-23 ZA ZA2014/03793A patent/ZA201403793B/en unknown
- 2014-05-26 IL IL23278914A patent/IL232789B/en active IP Right Grant
- 2014-06-05 IL IL232967A patent/IL232967A0/en unknown
- 2014-06-05 CL CL2014001472A patent/CL2014001472A1/es unknown
- 2014-07-02 CO CO14142113A patent/CO7000746A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141297A1 (es) | Formulaciones peptidicas robustas de liberacion controlada | |
| CL2013003365A1 (es) | Formulacion farmaceutica que comprende diacilglicerol y/o tocoferol, fosfatidilcolina, solvente mono-alcoholico organico biocompatible que comprende etanol, solvente polar, y un analogo de somatostatina como principio activo; proceso para prepararla; kit farmaceutico; uso en el tratamiento de acromegalia y canceres, entre otros. | |
| MX2014015657A (es) | Composicion topica que comprende un polimero formador de pelicula para liberar un ingrediente activo a la piel. | |
| PH12014502778A1 (en) | Antibody formulation | |
| CO6251200A2 (es) | Metodo para modular la tasa de liberacion de ingredientes activos microencapsulados usado paa la proteccion de cultivos | |
| PE20160681A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| CL2015001945A1 (es) | (divisional de la solicitud n° 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos. | |
| AR081535A1 (es) | Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso | |
| PE20110642A1 (es) | Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso | |
| BR112016006171A2 (pt) | formulações de espuma e dispositivo para sua entrega | |
| MX345256B (es) | Formulaciones estables para inyeccion parenteral de farmacos de molecula pequeña. | |
| MX2019003520A (es) | Mezclas y formulacions que comprenden una sal de alquil amonio de acido etilendiaminotetraacetico (edta). | |
| PE20160850A1 (es) | Sistema multiparticulado para administrar drogas | |
| BR112013028531A2 (pt) | composição inseticida líquida | |
| UA116886C2 (uk) | Препаративна форма йодосульфурон-метилу натрієвої солі | |
| PE20141068A1 (es) | Formulaciones topicas de tipo suspension que comprenden depsipeptido ciclico | |
| MX2015007424A (es) | Composiciones y/o articulos con solubilidad mejorada de un activo solido. | |
| BR112017017643A2 (pt) | formulação farmacêutica tópica | |
| MX350964B (es) | Formulaciones de agonistas del receptor de somatostatina. | |
| PE20110283A1 (es) | Composicion que contiene nifurtimox | |
| AR061802A1 (es) | Composicion que tiene una actividad que previene la germinacion, procedimientos para obtener dichas composiciones y uso de las mismas | |
| BR112014031463A2 (pt) | composição pesticida na forma de emulsão aquosa | |
| MX342069B (es) | Formulaciones farmacéuticas que comprenden un fosfolípido como mejorador de la penetración de un principio activo en la piel. | |
| AR086252A1 (es) | Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo | |
| WO2011162560A3 (ko) | 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |